Ketamine on Public Funding in Norway (2026): Who Qualifies

Yes — but the funded drug is not the one most of Europe pays for. Since 25 August 2025, Norway's public health system funds generic intravenous ketamine for treatment-resistant depression — a world-first national decision — while esketamine nasal spray (Spravato) was rejected and is not funded. For eligible patients, treatment in the public specialist service costs at most standard co-payments. This page covers who qualifies, how the referral chain works, what you pay, and the routes if you fall outside the criteria; the eligibility decision itself always sits with a clinician, and you can begin orienting yourself with our eligibility check.

What is covered

On 25 August 2025, Beslutningsforum for nye metoder — the body that decides what Norway's public specialist health service adopts — decided that generic IV ketamine may be used and publicly funded for treatment-resistant depression, effective the same day (Nye Metoder, ID2022_018). No other country funds generic racemic ketamine for depression at the national level; Psychedelic Alpha called it a world first. The proposal came from Sykehuset Østfold, whose clinicians built the Norwegian evidence and protocol base.

The funding comes with conditions. Treatment takes place in the public specialist service only — hospitals and DPS centres (distriktspsykiatriske sentre), not private practice. Because ketamine is not licensed for depression, patients give written consent acknowledging off-label use, and every treated patient is followed through a registry or clinical study. The decision has a built-in expiry check: re-evaluation by the end of 2028, with an updated evidence review already commissioned in April 2026.

What is not covered: Spravato. Beslutningsforum said no three times — 26 April 2021, 25 October 2021 and 18 October 2022 — citing evidence quality and price, and declined a reassessment in 2025 (Nye Metoder, ID2019_116).

Who qualifies

The pathway is for treatment-resistant depression confirmed in the public specialist service — in practice, documented failure of adequate previous treatments in the current episode. The practical currency is a written treatment history: every antidepressant and therapy tried, with substance, dose, duration and outcome. Assemble it before any appointment — it does more work than anything you say in the room.

Who decides and how to apply

The route follows the standard Norwegian referral chain. Your fastlege (regular GP) refers you to specialist mental health care; a DPS or hospital psychiatric department assesses whether your depression counts as treatment-resistant; the local treatment team then decides per its protocol. The national decision entitles appropriate patients across the country to this treatment, but each hospital trust builds its own capacity, so what is offered — and how soon — varies by region. If your local unit has no programme yet, ask the assessing psychiatrist what the nearest offering unit is. The full picture of every legal route is in our Norway access guide; to see who is listed, browse providers in Norway.

What it costs you

Within the public specialist service you pay at most standard outpatient co-payments, which count toward the annual frikort exemption ceiling — once you reach it, care is free for the rest of the year. The private comparison is stark: Oslo clinics charge roughly NOK 4,250–7,590 per session, with published programmes from about NOK 12,750 to 47,640, entirely self-pay.

If you do not qualify

Private ketamine clinics. Axonklinikken (Oslo and Trondheim) and Synapseklinikken (Oslo) treat legally after their own medical and psychological screening, without a referral, at the self-pay prices above. Screening quality is the thing to check — see our clinic-choice guide.
Clinical trials are free by definition. The one recruiting Norwegian study in July 2026 is KeDA, a ketamine trial for combined depression and alcohol use disorder in Tromsø — see the trials guide for how to search.
No Spravato fallback exists. There is no funded esketamine route in Norway; the public system channels this patient group to the generic ketamine pathway instead.

Frequently asked questions

Is ketamine treatment free in Norway?

Publicly funded, yes — in the public specialist service you pay at most standard specialist-care co-payments, which count toward the frikort ceiling; after that, care is free for the rest of the year. Private clinic treatment is fully self-pay.

Is Spravato reimbursed in Norway?

No. Beslutningsforum rejected it three times between 2021 and 2022 and declined a reassessment in 2025 — but generic IV ketamine is publicly funded for the same patient group, the reverse of most European countries.

Do I need a referral for the public pathway?

Yes. Your fastlege refers you to a DPS or hospital psychiatric department, which confirms treatment resistance and decides per its local protocol. Bring a written record of every treatment you have tried.

What happens in 2028, and how does Norway compare with the rest of Europe?

The funding decision is conditional: registry and study data feed a re-evaluation due by the end of 2028, so the pathway could be confirmed, tightened or changed. For how Norway's choice compares with the Spravato-reimbursing systems elsewhere, see the Europe-wide reimbursement map.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with your insurer and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.

Ketamine on Public Funding in Norway: The 2026 Coverage Guide

On this page